期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 269, 期 1-2, 页码 87-89出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.02.004
关键词
Multiple sclerosis; Glia; Cerebrospinal fluid; Biomarker; Immunotherapy
资金
- Swedish Research Council [K2009-65X-15424-05-3, K2011-X-20401-05-6]
- Swedish Federal Government under the LUA/ALF agreement
- Arosenius Foundation
- Wilhelm and Martina Lundgren Science Foundation
- Knut and Alice Wallenberg Foundation
- Swedish Society of the Neurologically Disabled
- Research Foundation of the Multiple Sclerosis Society of Gothenburg
- Edit Jacobson Foundation
- BiogenIdec
The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to immunosuppressive treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by immunosuppressive treatment. 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据